StockData
Merck & Co., Inc. logo

Merck & Co., Inc. (MRK) operating KPIs

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)

Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%

Merck bravecto (fluralaner parasiticides line) — Quarterly sales Q1–Q3 ($M; Q4 not separately disclosed) ($M)

Form 10-Q Animal Health MD&A (published for Q1, Q2, Q3; full year published in $B in Form 10-K)

Latest, Q2 2026
359
Period ended Jun 30, 2026
Change on a year earlier
+7.2%
335 in Q2 2025
History
8 quarters
Since Q1 2022
Sources
7
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedBravecto (fluralaner parasiticides line) — Quarterly sales Q1–Q3 ($M; Q4 not separately disclosed) ($M)Year on yearSource
Q2 2026Jun 30, 2026359+7.2%Form 10-Q (mrk-20260630.htm, filed 2026-08-07) ↗
Q1 2026Mar 31, 2026379–Form 10-Q (mrk-20260331.htm, filed 2026-05-04) ↗
Q3 2025Sep 30, 2025262-1.5%Form 10-Q (mrk-20250930.htm, filed 2025-11-05) ↗
Q2 2025Jun 30, 2025335–Form 10-Q (mrk-20250630.htm, filed 2025-08-05) ↗
Q3 2024Sep 30, 2024266+13.2%Form 10-Q (mrk-20240930.htm, filed 2024-11-06) ↗
Q3 2023Sep 30, 2023235–Form 10-Q (mrk-20230930.htm, filed 2023-11-03) ↗
Q1 2023Mar 31, 20233140.0%Form 10-Q (mrk-20230331.htm, filed 2023-05-05) ↗
Q1 2022Mar 31, 2022314–Form 10-Q (mrk-20230331.htm, filed 2023-05-05) ↗

Breakdown

What makes up bravecto (fluralaner parasiticides line) — quarterly sales q1–q3 ($m; q4 not separately disclosed)

Cite this data

StockData. (2026). Merck Bravecto (fluralaner parasiticides line) — Quarterly sales Q1–Q3 ($M; Q4 not separately disclosed) ($M), quarterly Q1 2022–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev_bravecto_q

See every metric in the Merck KPI table. Data updated Oct 26, 2026.